OPEN COMPANY INTELLIGENCEPublicly Listed Biopharma · Companies
Matching companies load automatically. Browse 24 companies per page; expand filters to narrow the results.
73JCR Pharmaceuticals is a Japan-based research-oriented biopharmaceutical company specializing in therapies for rare and genetic diseases. Its scientific work includes biologics and a proprietary blood-brain-barrier delivery technology for central nervous system applications. The company is also involved in regenerative and other advanced medicinal approaches. Its official Japanese and English corporate information confirms headquarters in Ashiya, Hyogo, and a Tokyo Stock Exchange Prime Market listing under 4552. These capabilities support programs focused on rare genetic conditions and central nervous system delivery.
74Kyowa Kirin is a Japanese global specialty pharmaceutical company developing and commercializing medicines for serious and often underserved conditions. Its research capabilities include antibody-based medicines and other biologic or targeted therapeutic approaches supported by clinical development and specialized manufacturing. The company has long worked in rare diseases and selected hematology and immunology markets. Based in Japan, Kyowa Kirin is listed on the Tokyo Stock Exchange under security code 4151. This directory records its stable therapeutic activities and technology orientation, without attempting to track every product indication or licensing agreement.
75Ono Pharmaceutical is a Japanese prescription-drug company engaged in discovery, clinical development and commercialization of therapies for serious diseases. Its research and development strategy uses small molecules, biologics and selected externally partnered technologies to address oncology, immune conditions and other specialty therapeutic needs. The company also collaborates with academic institutions and biotechnology developers to expand its drug discovery capabilities. Ono is headquartered in Japan and trades on the Tokyo Stock Exchange under ticker 4528.
76Otsuka Holdings is a Japanese listed holding company whose group businesses include pharmaceutical discovery, development and commercialization alongside other healthcare activities. Its pharmaceutical operations support research into central nervous system disorders, oncology and selected specialty indications through group companies. The parent is based in Japan and trades on the Tokyo Stock Exchange under securities code 4578. This entry describes the listed group's innovative therapeutic business without treating its wider consumer and nutrition businesses as drug development.
77ALTEOGEN is a South Korean biotechnology company developing technologies for biologic medicines and drug delivery. Its research includes enzymes and formulations designed to enable alternative administration of therapeutic antibodies, as well as additional biologic improvement and development approaches. The company works with pharmaceutical partners that may incorporate its platform technologies into therapeutic products. ALTEOGEN is listed on the Korean KOSDAQ market under code 196170 and maintains its corporate operations in South Korea. Official company reports provide the latest clinical, licensing and financial information.
78Celltrion is a South Korean biopharmaceutical company engaged in biologic medicine development, manufacture and commercialization. Its operations include antibody therapeutics and biosimilars, with ongoing pharmaceutical research relevant to autoimmune diseases, oncology and other inflammatory conditions. As a large biologics developer, Celltrion integrates analytical, process and clinical capabilities with global marketing partnerships. The company is listed on the KOSPI market under code 068270 and is based in Incheon, South Korea. This directory represents the listed pharmaceutical issuer rather than treating individual subsidiary brands or distribution arrangements as separate issuers.
79Orum Therapeutics is a South Korean biotechnology company developing targeted therapeutic approaches that combine antibody delivery with protein degradation technologies. Its company FAQ describes degrader-antibody conjugates and a platform intended for treatment of cancers, including hematologic malignancies. The same official source identifies its KOSDAQ listing under 475830. This directory captures a stable issuer identity, scientific platform and disease classification; the current clinical portfolio and experimental results should instead be checked against original company announcements and regulatory records. Listing status remains subject to subsequent exchange updates.
80Beijing Kawin Technology Share-Holding is a China-based biopharmaceutical developer working on treatments for viral and immune-related diseases. Its corporate description identifies an innovative drug-discovery and development focus supported by internal research and pharmaceutical-development capabilities. The Shanghai Stock Exchange STAR Market company page corroborates the issuer and its stock code 688687, while the official company website describes its research platforms and corporate history. Its drug-development programs focus on antiviral and immunology-related therapeutic approaches.
81Hemab Therapeutics is a biotechnology company developing investigational medicines for inherited and other serious disorders of blood coagulation. Its therapeutic research focuses on treatments intended to address conditions associated with abnormal bleeding and clot formation. The company conducts development activities spanning biological medicines and clinical research, with operations in the United States and Denmark. Hemab operates as a publicly listed issuer and makes corporate disclosures available through its investor relations website.
82Obsidian Therapeutics is a publicly traded biotechnology company developing engineered tumor infiltrating lymphocyte therapies for people with solid tumors. Its research uses regulated protein activity to influence selected functions of modified immune cells, with a focus on investigational cancer treatments. Obsidian became publicly traded in 2026 through a corporate transaction involving Galera Therapeutics. Its current issuer identity and earlier corporate history should be understood together, rather than as separate active public companies.
83Absci is a biotechnology company that combines artificial intelligence with experimental biology to discover and design therapeutic antibodies. Its approach links computational protein design to laboratory testing, with the goal of creating antibody candidates that can be investigated in drug development. Absci pursues internal therapeutic research and also works with pharmaceutical collaborators on selected programs. The company is distinct from a software-only or contract-service provider because its activities include the development of investigational therapeutic molecules. The official corporate and investor relations websites provide the appropriate sources for updated information about specific research programs, collaborations and securities disclosures.
84Actuate Therapeutics is a publicly traded United States biotechnology company developing investigational cancer medicines, including programs based on modulation of GSK-3 beta. The company is headquartered in Fort Worth, Texas, and its common shares are registered on Nasdaq under ACTU. In October 2026, it disclosed Nasdaq continued-listing deficiency notices concerning minimum bid price and market value requirements. The notices expressly stated that trading continued and did not constitute immediate delisting, although compliance was unresolved.
85Adicet Bio is a biotechnology company developing investigational cell therapies for serious diseases. Its research has included allogeneic gamma delta T-cell approaches, cellular engineering and chimeric antigen receptor technologies, with therapeutic applications in autoimmune conditions and cancer. The company has also described research involving in vivo cell engineering. Its business is centered on advancing therapeutic candidates rather than providing contract manufacturing as its primary activity. Adicet publishes corporate information, dated research updates and public-company disclosures through its official website and investor relations portal.
86Aktis Oncology is a biotechnology company developing targeted radiopharmaceutical medicines for the treatment of solid tumors. Its scientific approach investigates ways to deliver radioactive payloads to selected tumor tissues using targeting technologies, with the aim of improving precision in cancer treatment. Aktis conducts therapeutic research and clinical development, and its programs are investigational unless specifically supported by a regulatory approval. The company began public trading in 2026 and publishes issuer information through its investor relations website. Readers can use its official company and investor resources to examine the current clinical pipeline, securities filings and corporate announcements.
87Aldeyra Therapeutics is a biotechnology company researching and developing investigational medicines for immune-mediated diseases, including conditions affecting the eye. Its work includes reactive aldehyde species modulators and other therapeutic approaches intended to influence inflammatory biology. The company focuses on discovering and advancing drug candidates rather than offering contract development services. Individual regulatory submissions, clinical trial results and potential marketing authorizations should be evaluated from dated official disclosures because those statuses can change. Aldeyra provides current business information and investor communications through its corporate and investor relations websites.
88Allarity Therapeutics is a United States clinical-stage biopharmaceutical company developing targeted medicines for oncology. Its principal therapeutic development program includes a drug candidate aimed at PARP and WNT pathway activity, supported by approaches intended to predict which patients may respond to treatment. The company has also expanded commercial laboratory services, but its continuing investigational drug development distinguishes it from a pure diagnostics provider. Allarity trades on Nasdaq under ALLR. A dated 2026 SEC filing identifies its principal executive office in Tarpon Springs, Florida, superseding older website references to Boston.
89AN2 Therapeutics is a biotechnology company focused on discovering and developing small-molecule medicines, drawing on a platform built around boron-based chemistry. Its research includes investigational treatments for infectious diseases and other conditions with significant medical need. AN2 undertakes therapeutic drug development and clinical research, distinguishing the company from businesses whose primary activity is supplying research services to others. Its official website and investor relations materials provide dated information about research priorities, drug candidates and public-company disclosures.
Coverage expands from sourced records; this database does not claim all biopharma companies.
